Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors

Chimeric antigen receptor T cells (CAR-Ts) targeted against CD19 have shown impressive activity in patients with B-cell leukemias and lymphomas. This has revolutionized the treatment landscape for patients with relapsed or refractory (r/r) disease, providing hope for a possible curative approach for those who previously had limited available treatment options. The success of this approach has prompted interest in studying CAR-Ts for other hematologic malignancies and the development of CARs specific for other antigens. In this review, we discuss recent developments in CAR-Ts in multiple myeloma (MM), Hodgkin lymphoma (HL), T-cell malignancies, and acute myelogenous leukemia (AML; Fig 1)